Reset

Print

# **United States Department of Labor**

Office of Workers' Compensation Programs
Division of Federal Employees' Compensation



OMB No. 1240-0055

Expires: 10/31/2019

# Authorization Request form and Certification/Letter of Medical Necessity for Opioid Medications.

This form is to be completed and signed by the patient's treating physician. Complete all sections of this form. Failure to complete this form in its entirety may result in delayed processing or an adverse determination for insufficient information. The form is valid and effective for up to 30 days following the date of the treating physician's signature/certification.

•	0.	,				
Part A - Patient Information						
1. Patient Name (Last, First, Middle Initial):			2. Patient OWCP #:			
3. Street Address:			4. Date of Birth (mm/dd/yyyy):			
5. City:	6. State:	7. Zip:	8. Phone #:			
Part B - Treating Physician	Information					
9. Treating Physician Name:			10. Treating Physician NPI#:			
11. Street Address:			12. Provider ID#:	13. DEA#:		
14. City:	15. State:	16. Zip:	17. Phone #:	18. Secure Fax #:		
Part C - Opioid Medication I	nformation-	PLEASE NOTE	LIMIT OF TWO			
19. Medication Name(s):			20. Primary Diagnosis:			
21. NDC(s):			22. ICD-10 Code:			
23. Directions for use:			24. Date of Last Physical Examination (mm/dd/yyyy):			
25. Route of Administration	1 2		26. Anticipated Length of	1 2		
(and Code):	☐ ☐ Oral (1)		Therapy:	☐ 7 days		
	☐ ☐ Topical (5)			☐ ☐ 14 days		
	☐ ☐ Injection (2)			☐ ☐ 30 days		
	☐ ☐ Other (specify route and code):			☐ ☐ 60 days		
				☐ ☐ 90 days		
			_	Other (specify):		
27. Daily morphine milligram	equivalent do	ose:				

Part D - Certification of Medical Necessity	
28. Have you accessed the requisite state Prescription Drug Monitoring Program, if available, regarding this patient's history of controlled substance prescriptions <u>and</u> will you do so every month thereafter?	☐ Yes ☐ No
29. Will you enter this prescription information into your state's Prescription Drug Monitoring Program?	☐ Yes ☐ No
30. Have you completed a urine drug test for the above-named patient <u>and</u> will you do so periodically?	☐ Yes ☐ No
31. Is the patient receiving a benzodiazepine from you or any other provider while receiving an opioid prescription?	☐ Yes ☐ No
32. Have you discussed realistic benefits and known risks of opioid therapy with the patient, and have you advised the patient that serious risks include potentially fatal respiratory depression and development of a potentially serious lifelong opioid use disorder?	☐ Yes ☐ No
33. Did you evaluate the use of non-opioid alternatives and conclude with reasonable medical certainty that the opioid's expected benefits for both pain and function outweigh the risk to the patient? SUPPLY NARRATIVE IN ITEM 40.	☐ Yes ☐ No
34. Have you evaluated the patient for risk of opioid use disorder, potential need for medication-assisted treatment (MAT), and believe the medical benefit of prescribing the opioid outweighs the risk? SUPPLY NARRATIVE IN ITEM 40.	☐ Yes ☐ No
35. Have you discussed with the patient the potential risk for opioid overdose or other adverse reaction and the steps the patient can take to reduce their risk, such as not combining their opioid with alcohol or other sedating substances?	☐ Yes ☐ No
36. For patients who are at increased risk for overdose (as defined in the CDC guidelines) have you offered a prescription for overdose reversal (for example, naloxone) or counseled the patient to obtain naloxone from their pharmacy, where available without a prescription?	☐ Yes ☐ No
37. Has use of the opioid medication(s) improved both pain and function for the patient?	☐ Yes ☐ No
38. Is the opioid medication medically necessary for its intended use?	☐ Yes ☐ No

E E e Ia	BEING USED, LIST EACH) AND EXPLA effective and medic avender oil, and all eturned to the pro-	the compounded drug; IF I (INCLUDING NAME, NDC IN THE NEED FOR MORE ally necessary ingredien pha-lipoic acid, cannot be vider. Herbal supplement	, QUANTITY E THAN TEN ts should be e authorized ts are author	, STRENGT IN ITEM NU used. Herk on this forn	H, AND ME IMBER 40. pal supplem n and will c	DICAL NECESSITY FOR Only the most cost lents, such as resverations ause the form to be	rol,
t	he OWCP Chief Me	edical Officer or his/her do Drug Name:	<b>esignee.</b> NDC:	Quantity:	Strength:	Medically Necessary?	
	Ingredient #1	Drag Hame.	1120.	Quantity.	- Carongan	☐ Yes ☐ No	
	Ingredient #2					☐ Yes ☐ No	
	Ingredient #3					☐ Yes ☐ No	
	Ingredient #4					☐ Yes ☐ No	
	Ingredient #5					☐ Yes ☐ No	
	Ingredient #6					☐ Yes ☐ No	
	Ingredient #7					☐ Yes ☐ No	
	Ingredient #8					☐ Yes ☐ No	
	Ingredient #9					☐ Yes ☐ No	
	Ingredient #10					☐ Yes ☐ No	
li c u p	terature to support yompounded drug. is see of this medication	explaining why the opioid mayour opinion on the necession on the necession may be asked to provion. The need for this mediconstructions in item number	ity of the med de clinical do ation is subje	dication, part cumentation act to review	icularly if the and other re by claims st	e opioid is part of a elevant evidence to supp aff and medical	ort
I certify that I am the treating physician for the above-named patient and that the medication requested is medically necessary and cost effective for the patient. I further certify, under penalty of law, that the information provided on this form is true and correct to the best of my knowledge, and that documentation supporting this information is available for review if requested. I understand that any person who knowingly makes any false statement or misrepresentation to obtain prescription drugs from OWCP is subject to administrative penalties including provider exclusion; civil penalties including those under the False Claims Act and/or criminal prosecution. The submission of this form signifies my certification of the above and the on-file signature on my provider enrollment form is hereby incorporated by reference.							
41. \$	Signature/CERTIFIC	CATION of Patient's Treating	g Physician:		☐ Ye	s 42. Date	
						E 04 07 5	S

39. If the requested opioid medication is prescribed in a compounded drug, complete the following for each active and

### Instructions

#### PART A - Patient Information

- Provide the patient's name in this order: last name, first name, middle initial.
- 2. Provide the patient's Office of Worker's Compensation Programs (OWCP) claim number. The OWCP claim number is the unique 9-digit number that OWCP assigns to the patient's (claimant's) workers' compensation claim.
- 3. Provide the street address of the patient's residence (with unit or apartment number, if applicable).
- 4. Provide the patient's date of birth, including the month, date, and year.
- 5. Provide the city where the patient's residence is located.
- 6. Provide the state where the patient's residence is located.
- 7. Provide the zip code where the patient's residence is located.
- 8. Provide the patient's phone number.

## **PART B - Treating Physician Information**

- 9. Provide the treating physician's name.
- 10. Provide the treating physician's National Provider Identifier (NPI) number. The NPI number is a unique, 10digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
- 11. Provide the street address of the treating physician's office (with unit or suite number, if applicable).
- 12. Provide the treating physician's Provider ID number. The Provider ID number is the 9-digit identification number assigned to health care providers enrolled in OWCP's Web Bill Processing Portal.
- 13. Provide the treating physician's Drug Enforcement Administration (DEA) Number. The DEA number is a number assigned to health care providers by the DEA that allows providers to write prescriptions for controlled substances.
- 14. Provide the city where the treating physician's office is located.
- 15. Provide the state where the treating physician's office is located.
- 16. Provide the zip code where the treating physician's office is located.
- 17. Provide the treating physician's office telephone number.
- 18. Provide the treating physician's secure office fax number. A secure fax line is one that meets or exceeds the requirements for HIPAA privacy and security.

## PART C - Opioid Medication Information. Note that OWCP generally limits opioid medications to no more than 2 concurrently prescribed.

- 19. Provide the name of the opioid medication(s) prescribed by the patient's treating physician.
- 20. Provide the patient's primary diagnosis that warrants the opioid medication(s) prescribed.
- 21. Provide the National Drug Code (NDC) for the opioid medication(s) prescribed. The NDC is a unique, threesegment number that serves as a universal product identifier for drugs.
- 22. Provide the ICD-10 code for the primary diagnosis. The International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) is a coding of diseases, signs, and symptoms, abnormal findings, complaints, social circumstances and external causes of injury or diseases, as classified by the World Health Organization. The code set allows more than 14,400 different codes and permits the tracking of diagnoses.
- 23. Provide the direction for the opioid medication(s) prescribed. The direction of a medication is the amount and rate of occurrence at which the drug is given (e.g. 1 tablet every 12 hours). If two opioid medications are prescribed, provide the direction for each. The prescription(s) must be limited to a 30-day or less supply.
- 24. Provide the date at which the treating physician last conducted a medical examination of the patient. The medical examination must have been in person and have occurred within 2 weeks of the date of signature on this form.

- 25. Mark an "X" next to the applicable route of administration if it is oral, topical, or by injection. If the route of administration is not oral, topical, or by injection, mark "other" and specify the manner of administration and Route Code. For example: Intravenous (A); Buccal (B); Intramuscular (C); Dental (D); Perfusion (F); Inhalation (H); Translingual (L); Miscellaneous (M); Intraperitoneal (P); Irrigation (R); Sublingual (S); Transdermal (T); Urethral (U); Vaginal (V); Rectal (3); Mucous Membrane (4); Ophthalmic (6); Nasal (7); Otic (8); Intradermal (9).
- 26. Mark an "X" next to "7 days," "14 days," "30 days," "60 days," or "90 days" to indicate the anticipated length of treatment for each medication; if it is shorter than 7 days, longer than 90 days or not otherwise listed, mark "other" and specify the anticipated length of treatment.
- 27. Provide the daily morphine milligram equivalent (MME) dose. The daily MME is the amount of morphine an opioid dose is equivalent to when prescribed. The MME prescribed should be the lowest effective dosage. The Centers for Disease Control and Prevention has resources that can help providers quickly calculate this.

## PART D Certification of Medical Necessity - Responses are Mandatory

- 28. Mark "yes" or "no" to the guestion.
- 29. Mark "yes" or "no" to the guestion.
- 30. Mark "yes" or "no" to the question.
- 31. Mark "yes" or "no" to the question.
- 32. Mark "yes" or "no" to the question.
- 33. Mark "yes" or "no" to the question.
- 34. Mark "yes" or "no" to the question. Medication-assisted treatment (MAT) is the use of Food and Drug Administration-approved medications, such as buprenorphine, buprenorphine-naloxone combination products, methadone, and naltrexone in combination with counseling, other behavioral therapies, and patient monitoring to provide treatment for opioid use disorders.
- 35. Mark "yes" or "no" to the question.
- 36. Mark "yes" or "no" to the question.
- 37. Mark "yes" or "no" to the question.
- 38. Mark "yes" or "no" as to whether the opioid medication prescribed is medically necessary.
- 39. If the requested opioid medication is prescribed in a compounded drug, list each active and inactive ingredient in the compounded drug by name, NDC, quantity, and strength and mark "yes" or "no" to the question of whether the ingredient is medically necessary. The quantity must be expressed in units such as milligrams, micrograms, drops, etc. The strength is the amount of drug in a given dosage form (e.g. 500 mg/tablet). Each ingredient (active and inactive) in the compounded drug must be medically necessary for treatment and for delivery of the compounded drug, and should be at the lowest possible cost to perform its function.
- 40. Provide a narrative explaining why the opioid medication is medically necessary. You may cite relevant medical literature to support your opinion on the necessity of the medication, particularly if the opioid is part of a compounded drug. The information on this form, including the narrative, is subject to review by claims staff and medical personnel. The treating physician submitting the form may be asked to provide additional documentation in support of his/her certification of medical necessity. Provide the required detail with all information required in item 39 for additional ingredients if the prescribed opioid is within a compounded drug with more than ten ingredients.
- 41. Affirm the treating physician's signature/certification by making an "X" in the box.
- 42. Provide the date of the treating physician's signature/certification.

### **Public Burden Statement**

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. If you have any comments regarding the burden estimate or any other aspect to this collection of information, including suggestions for reducing this burden, send them to the Office of Workers' Compensation Programs, U.S. Department of Labor, Room S3524, 200 Constitution Avenue, N.W., Washington, D.C. 20210. Do not submit the completed claim form to this address. Persons are not required to respond to this information collection unless it displays a currently valid OMB number.

## **Privacy Act Statement**

In accordance with the Privacy Act of 1974, as amended (5 U.S.C. 552a), you are hereby notified that: (1) The Federal Employees' Compensation Act (FECA), as amended and extended (5 U.S.C. 8101, et seq.) is administered by the Office of Workers' Compensation Programs of the U.S. Department of Labor, which receives and maintains personal information on claimants and their immediate families. (2) Information which the Office has will be used to determine eligibility for and the amount of benefits payable under the FECA, and may be verified through computer matches or other appropriate means. (3) Information may be given to the Federal agency which employed the claimant at the time of injury in order to verify statements made, answer questions concerning the status of the claim, verify billing, and to consider issues relating to entitlement to benefits or other relevant matters. (4) Information may be given to Federal, state and local agencies for law enforcement purposes, to obtain information relevant to a decision under the FECA, to determine whether benefits are being paid properly, including whether prohibited dual payments are being made, and, where appropriate, to pursue salary/administrative offset and debt collection actions required or permitted by the FECA and/or the Debt Collection Act. (5) Failure to disclose all requested information may delay the processing of the claim or the payment of benefits, or may result in an unfavorable decision or reduced level of benefits.

#### Notice

If you have a disability, Federal law gives you the right to receive help from the OWCP/DFEC in the form of communication assistance, accommodation(s) and modification(s) to aid you. For example, OWCP/DFEC will provide you with the copies of documents in alternate formats, communication services such as sign language interpretation, or other kinds of adjustments or changes to accommodate your disability. Please contact OWCP/DFEC to ask about this assistance.